摘要
目的:研究拉呋替丁片在健康人体内的药动学。方法:12名健康受试者口服10mg拉呋替丁片后,采用液-质联用法测定血浆中拉呋替丁浓度。结果:拉呋替丁的达峰时间和峰浓度分别为(1.3±0.4)h和(158.6±41.6)μg.L-1,AUC0-24为(882.0±306.1)μg.h-1.L-1,AUC0-∞为(898.8±316.4)μg.h-1.L-1,根据口服给药二室模型估算的t1/2α为(1.45±0.14)h,t1/2β为(4.4±0.4)h,清除率(CL/F)为(12.3±4.1)h-1。结论:该拉呋替丁片在男性和女性健康受试者的t1/2、Cmax、CL/F、AUC0-24和AUC0-∞相近(P>0.05),tmax有性别差异(P<0.05),单剂量口服其代谢特征基本与文献报道参数一致。
OBJECTIVE To study the pharmacokinetics of lafutiding tablets in healthy volunteers. METHODS The plasma concentrations of lafutiding tablets were determined by LCMS methods after the lafutiding tablets （10 mg） were given to the 12 healthy volunteers. RESULTS tmax was （1.3±0. 4） hours. Cmax was（158. 6 ± 41. 6）μg·L^-1 ,AUC0-24was （882.0±306. 1）μg·h^-1·L^-1, AUC0-∞ was （898.8 ± 316. 4）μg·h^-1·L^-1. The t1/2α of estimate was（ 1.45 ± 0. 14 ） hours, t1/2β was （4. 4 ± 0. 4） hours, CL/F was （12. 3 ± 4. 1） h^-1. CONCLUSION The t1/2, Cmax,CL/F, AUC0-24 and AUC0-∞ about the lafutiding tablets in male healthy volunteers is similar to the female healthy volunteers＇s（P〉0. 05） . tmax is different between female and male（P〈0. 05）, the results show that there was no significant difference in pharmacokinetics compared with the reported reference.
出处
《中国医院药学杂志》
CAS
CSCD
北大核心
2008年第19期1682-1684,共3页
Chinese Journal of Hospital Pharmacy
关键词
拉呋替丁片
药动学
液质联用法
lafutiding tablets
pharmacokinetics
method of LC-MS
